JP2019516754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516754A5 JP2019516754A5 JP2018561512A JP2018561512A JP2019516754A5 JP 2019516754 A5 JP2019516754 A5 JP 2019516754A5 JP 2018561512 A JP2018561512 A JP 2018561512A JP 2018561512 A JP2018561512 A JP 2018561512A JP 2019516754 A5 JP2019516754 A5 JP 2019516754A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- population
- pluripotent cells
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 29
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 11
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 9
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 230000014509 gene expression Effects 0.000 claims 5
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 4
- 229960000604 valproic acid Drugs 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108010016918 Histone-Lysine N-Methyltransferase Proteins 0.000 claims 3
- 102000000581 Histone-lysine N-methyltransferase Human genes 0.000 claims 3
- 230000003750 conditioning effect Effects 0.000 claims 3
- 239000002532 enzyme inhibitor Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010055008 Gastric sarcoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 229950008805 abexinostat Drugs 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 229950005837 entinostat Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000003471 mutagenic agent Substances 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 2
- 229960005184 panobinostat Drugs 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110028A JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
| JP2024168499A JP2025000812A (ja) | 2016-05-25 | 2024-09-27 | 癌を処置するための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305607 | 2016-05-25 | ||
| EP16305607.0 | 2016-05-25 | ||
| PCT/EP2017/062604 WO2017202949A1 (en) | 2016-05-25 | 2017-05-24 | Methods and compositions for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110028A Division JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516754A JP2019516754A (ja) | 2019-06-20 |
| JP2019516754A5 true JP2019516754A5 (cg-RX-API-DMAC7.html) | 2020-07-09 |
| JP7563872B2 JP7563872B2 (ja) | 2024-10-08 |
Family
ID=56131478
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561512A Active JP7563872B2 (ja) | 2016-05-25 | 2017-05-24 | 癌を処置するための方法及び組成物 |
| JP2022110028A Active JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
| JP2024168499A Pending JP2025000812A (ja) | 2016-05-25 | 2024-09-27 | 癌を処置するための方法及び組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110028A Active JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
| JP2024168499A Pending JP2025000812A (ja) | 2016-05-25 | 2024-09-27 | 癌を処置するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11458194B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3463433A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7563872B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20240103039A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116376812A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017270234B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018074192A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3025057A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL263224B2 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2741786C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017202949A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3484478B1 (en) | 2016-07-15 | 2025-11-05 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| EP3713596A1 (en) | 2017-11-24 | 2020-09-30 | Institut National de la Santé Et de la Recherche Médicale | Methods and compositions for treating cancers |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| SG11202006160RA (en) * | 2018-01-02 | 2020-07-29 | Khloris Biosciences Inc | Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer |
| JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス，インク． | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
| EP3833383A1 (en) | 2018-08-06 | 2021-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
| US20220154219A1 (en) * | 2019-03-22 | 2022-05-19 | The Johns Hopkins University | Gene delivery particles to induce tumor-derived antigen presenting cells |
| WO2020232373A1 (en) * | 2019-05-15 | 2020-11-19 | Board Of Regents, The University Of Texas System | Crispr methods for treating cancers |
| JP7352937B2 (ja) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット |
| CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
| GB202006254D0 (en) * | 2020-04-28 | 2020-06-10 | Institute Of Cancer Res | Anti-cancer vaccines and related therapy |
| KR20230036063A (ko) * | 2020-05-12 | 2023-03-14 | 러쉬 유니버시티 메디컬 센터 | 암을 치료하기 위한 조성물들 및 방법들 |
| CN112603995B (zh) * | 2020-12-30 | 2022-03-18 | 四川省肿瘤医院 | 靶向CAFs的肿瘤细胞疫苗、其制备方法及其应用 |
| KR20230163364A (ko) * | 2021-03-31 | 2023-11-30 | 셀레론 테라퓨틱스 리미티드 | 백신 보조제 |
| KR102795600B1 (ko) * | 2021-04-05 | 2025-04-15 | 주식회사 피노바이오 | 4'-티오-5-아자-2'-디옥시사이티딘 및 베네토클락스의 병용 요법 |
| WO2023159124A2 (en) * | 2022-02-17 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Methods for overcoming tazemetostat-resistance in cancer patients |
| CN115494237B (zh) * | 2022-09-19 | 2025-06-24 | 浙江省人民医院 | Rps6ka2在制备卵巢癌诊断试剂和治疗药物中的应用 |
| CN120936380A (zh) * | 2023-02-27 | 2025-11-11 | 武汉大学 | Pd-1信号调控及疾病治疗 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4806476A (en) | 1983-09-08 | 1989-02-21 | Lovelace Medical Foundation | Efficient cell fusion process |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| EP0380646B1 (en) | 1988-08-04 | 1999-01-20 | Amrad Corporation Limited | Use of leukaemia inhibitory factor (lif) for the (in vitro) propagation of embryonic stem cells |
| US5240840A (en) | 1991-04-05 | 1993-08-31 | Regents Of The University Of Michigan | Dna superfragment cloning |
| JP3314241B2 (ja) | 1992-04-06 | 2002-08-12 | ヤマハ発動機株式会社 | 自動二輪車用エンジンの排気浄化装置 |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| HUT74451A (en) | 1993-07-15 | 1996-12-30 | Cancer Res Campaign Tech | Prodrugs of protein tyrosine kinase inhibitors, systems contg. them and process for preparing them |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| CN1145614C (zh) | 1996-04-12 | 2004-04-14 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物 |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| AU729377B2 (en) | 1997-10-23 | 2001-02-01 | Asterias Biotherapeutics, Inc. | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
| US6835867B1 (en) | 1998-06-24 | 2004-12-28 | Richard P. Woychik | Allelic series of genomic modifications in cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| AU5889100A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| AU6605200A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2250186T3 (es) | 1999-09-10 | 2006-04-16 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| GEP20053530B (en) | 1999-10-19 | 2005-05-25 | Merck & Co Inc | Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1226119B1 (en) | 1999-10-19 | 2005-03-16 | MERCK & CO. INC. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| NL1017973C2 (nl) | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
| WO2002018549A1 (en) | 2000-08-30 | 2002-03-07 | Maria Biotech Co., Ltd. | Human embryonic stem cells derived from frozen-thawed embryo |
| US7250255B2 (en) | 2001-05-31 | 2007-07-31 | Shinya Yamanaka | Genes with ES cell-specific expression |
| EP1404672B1 (en) | 2001-06-22 | 2006-01-18 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6927293B2 (en) | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US7592177B2 (en) | 2003-11-10 | 2009-09-22 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| CA2659021A1 (en) | 2006-07-20 | 2008-01-24 | Richard Burt | Method of using mitotically inactivated stem cells for damaged tissue repair |
| CN101626763A (zh) | 2006-12-06 | 2010-01-13 | 北海道公立大学法人札幌医科大学 | 使用组蛋白脱乙酰酶（hdac）抑制物的细胞免疫增强 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| SG10201400329YA (en) | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5888753B2 (ja) | 2010-11-04 | 2016-03-22 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
| US9534206B2 (en) * | 2010-12-16 | 2017-01-03 | General Electric Company | Cell carrier, associated methods for making cell carrier and culturing cells using the same |
| US20130136722A1 (en) * | 2011-11-11 | 2013-05-30 | The Board Of Trustees Of The University Of Illinois | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
-
2017
- 2017-05-24 CN CN202211701185.XA patent/CN116376812A/zh active Pending
- 2017-05-24 KR KR1020247020115A patent/KR20240103039A/ko active Pending
- 2017-05-24 RU RU2018141200A patent/RU2741786C2/ru active
- 2017-05-24 WO PCT/EP2017/062604 patent/WO2017202949A1/en not_active Ceased
- 2017-05-24 CN CN201780045481.XA patent/CN109689089A/zh active Pending
- 2017-05-24 BR BR112018074192A patent/BR112018074192A8/pt not_active Application Discontinuation
- 2017-05-24 CA CA3025057A patent/CA3025057A1/en active Pending
- 2017-05-24 IL IL263224A patent/IL263224B2/en unknown
- 2017-05-24 JP JP2018561512A patent/JP7563872B2/ja active Active
- 2017-05-24 AU AU2017270234A patent/AU2017270234B2/en active Active
- 2017-05-24 KR KR1020187037459A patent/KR20190032295A/ko not_active Ceased
- 2017-05-24 EP EP17726274.8A patent/EP3463433A1/en active Pending
- 2017-05-24 US US16/303,705 patent/US11458194B2/en active Active
- 2017-05-24 KR KR1020227044304A patent/KR102677451B1/ko active Active
-
2022
- 2022-07-07 JP JP2022110028A patent/JP7622006B2/ja active Active
- 2022-07-28 US US17/815,586 patent/US20220370582A1/en active Pending
-
2023
- 2023-09-12 IL IL305882A patent/IL305882B2/en unknown
-
2024
- 2024-01-30 AU AU2024200549A patent/AU2024200549A1/en active Pending
- 2024-09-27 JP JP2024168499A patent/JP2025000812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516754A5 (cg-RX-API-DMAC7.html) | ||
| RU2018141200A (ru) | Способы и композиции для лечения опухолей | |
| JP2021504465A5 (cg-RX-API-DMAC7.html) | ||
| Mazzone et al. | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy | |
| JP5452231B2 (ja) | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン | |
| JP2022093564A (ja) | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 | |
| EP3474888B1 (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
| TW202134430A (zh) | 腫瘤細胞疫苗 | |
| Zhong et al. | Immunotherapy for hepatocellular carcinoma: current limits and prospects | |
| Schnekenburger et al. | Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments | |
| Du et al. | Hypothermic microenvironment plays a key role in tumor immune subversion | |
| RU2021132734A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| JP2013537187A5 (cg-RX-API-DMAC7.html) | ||
| JP2012515213A5 (cg-RX-API-DMAC7.html) | ||
| JP2018506995A5 (cg-RX-API-DMAC7.html) | ||
| JP2018048151A5 (cg-RX-API-DMAC7.html) | ||
| WO2016020434A1 (en) | Method for expanding immune cells | |
| Chang et al. | Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-α | |
| JP2020535832A5 (cg-RX-API-DMAC7.html) | ||
| CA3200513A1 (en) | Tumor cell vaccines | |
| Har-Noy et al. | Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma | |
| RU2014149080A (ru) | Препарат экзосом - ОНКОСОМ, способ его получения, способ профилактики злокачественных новообразований и способ иммунотерапии солидных опухолей с его использованием | |
| Teitz-Tennenbaum et al. | Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model | |
| Obertopp et al. | Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes | |
| Brown | Concomitant Delivery of Histone Deacetylase Inhibitor, MS-275, Enhances the Therapeutic Efficacy of Adoptive T Cell Therapy in Advanced Stage Solid Tumours |